Intensity Therapeutics Highlights INT230-6 Data in Advanced Solid Tumors at Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting November 8, 2018
Intensity Therapeutics Announces Preliminary Data from Clinical Study of INT230-6 in Advanced Solid Tumors October 22, 2018
Intensity Therapeutics to Present Preliminary Data from Clinical Study of INT230-6 at Upcoming Medical Conferences October 17, 2018
Intensity Therapeutics, Inc. Announces Presentation on INT230-6 Clinical Study at the 2018 ASCO conference. May 31, 2018
Intensity Therapeutics, Inc. Reports Positive Safety Data from On-going IT-01 Phase 1/2 Trial February 27, 2018
Intensity Therapeutics, Inc. Successfully Administers INT230-6 to First Patient in a Phase 1/2 Trial May 30, 2017
Intensity Therapeutics reports that INT230-6 Induces Protective T-Cell Immunity in preclinical models April 4, 2017
Intensity Therapeutics, Inc. Raises $10 Million to Fund Clinical Supplies Manufacturing and Phase I/II Trials of INT230-6 June 28, 2016
Intensity Therapeutics Issued First US Patent for Immune-based Cancer Therapeutic Agents June 2, 2016
Intensity Therapeutics reports that INT230-6’s Anti-cancer Mechanism is a Combination of Cell Death with Immune System Activation April 19, 2016
Intensity Therapeutics Preclinical Results Show AntiCancer Synergy of INT230-6 with Anti-PD-1 Compounds November 5, 2015
Intensity Therapeutics Forms Scientific Advisory Board Comprised of World-Leading Oncologists and Scientists October 22, 2015
Intensity Therapeutics, Inc. CEO to Speak at the 10th Annual Value-Based Oncology Management Forum October 12, 2015
Intensity Therapeutics, Inc.’s Research Selected for Presentation at the 2015 American Association for Cancer Research Annual Meeting April 16, 2015
